Clinical Trial Update: Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating an ocular sirolimus (rapamycin) formulation for age-related macular degeneration with choroidal neovascularization; the study was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Sirolimus ocular formulation (sirolimus)

Snippet

Sponsor: Santen Inc. | Conditions: Age-related Macular Degeneration, Choroidal Neovascularization | Phase 1, Phase 2 | Status: TERMINATED